#PRLD↓

PRLD/ 02/03/2026 · 11:20 AM

Prelude Therapeutics Gets FDA Green Light for Groundbreaking Blood Cancer Treatment

Prelude Therapeutics receives FDA clearance to begin testing PRT12396, a targeted therapy for myeloproliferative neoplasms affecting thousands of patients.

PRLD/ 11/04/2025 · 11:28 AM

Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs

Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.